Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle

被引:43
|
作者
Seelig, AS [1 ]
Al-Hasani, S [1 ]
Katalinic, A [1 ]
Schöpper, B [1 ]
Sturm, R [1 ]
Diedrich, K [1 ]
Ludwig, M [1 ]
机构
[1] Univ Clin Hosp, Dept Gynecol & Obstet, D-23538 Lubeck, Germany
关键词
cetrorelix; cryopreservation; GnRH agonist; GnRH antagonist; open freezing system;
D O I
10.1016/S0015-0282(01)03008-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the pregnancy rates of frozen-thawed 2-pronucleate (2PN) oocytes obtained either in a long protocol or in an antagonist protocol and ovarian stimulation with either human menopausal gonadotropin (hMG) or recombinant follicular stimulating hormone (recFSH). Design: Retrospective data analysis. Setting: Academic infertility center. Patient(s): Three hundred forty-two infertile couples who under-went a transfer of cryopreserved 2PN oocytes. Intervention(s): hMG (n = 194) or recFSH (n = 92) in a long protocol or hMG (n = 16) or recFSH (n = 40) stimulation under pituitary suppression with the GnRH antagonist Cetrotide was used. The 2PN oocytes were transferred after endometrial preparation using E, valerate and vaginal progesterone (Crinone 8% vaginal gel). Main Outcome Measure(s): Implantation, pregnancy, and abortion rates. Result(s): Implantation rates in the freeze-thaw cycles were 5.6% (hMG) and 3.8% (recFSH) with 2PN oocytes from the long protocol and 7% from the antagonist cycles, irrespective of whether hMG or reeFSH was used. Pregnancy rates were similar independent of whether they resulted from the long-protocol cycles with hMG (15.4%) and recFSH (13.1%) or from the antagonist protocol cycles with hMG (25.0%) and recFSH ( 17.5%. Conclusion(s): The potential to implant is independent of the gonadotropin-releasing hormone analogue and gonadotropin chosen for the collection cycle when previously cryopreserved 2PN oocytes were replaced after thawing in the cleavage stage. (Fertil Steril(R) 2002:77:472-5. (C)2002 by American Society for Reproductive Medicine.).
引用
收藏
页码:472 / 475
页数:4
相关论文
共 50 条
  • [41] Editorial Comment to Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer
    Kawahara, Takashi
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (10) : 837 - 838
  • [42] Gonadotropin-releasing hormone/gonadotropin-releasing hormone receptor signaling in the placenta
    Sasaki, Kirsten
    Norwitz, Errol R.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2011, 18 (06) : 401 - 408
  • [43] Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy Effects of Androgen-Deprivation Therapy
    Sun, Maxine
    Choueiri, Toni K.
    Hamnvik, Ole-Petter R.
    Preston, Mark A.
    De Velasco, Guillermo
    Jiang, Wei
    Loeb, Stacy
    Nguyen, Paul L.
    Quoc-Dien Trinh
    JAMA ONCOLOGY, 2016, 2 (04) : 500 - 507
  • [44] GONADOTROPIN-RELEASING HORMONE
    VALENTA, LJ
    ZOLMAN, JC
    NEW ENGLAND JOURNAL OF MEDICINE, 1977, 297 (13): : 725 - 725
  • [45] GONADOTROPIN-RELEASING HORMONE
    YEN, SSC
    ANNUAL REVIEW OF MEDICINE, 1975, 26 : 403 - 417
  • [46] GONADOTROPIN-RELEASING HORMONE
    KRETSER, DMD
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1975, 5 (06): : 585 - 586
  • [47] Gonadotropin-releasing hormone agonists: where do we stand?
    Nawroth, Frank
    GYNAKOLOGISCHE ENDOKRINOLOGIE, 2019, 17 (02): : 83 - 86
  • [48] DANAZOL BUT NOT GONADOTROPIN-RELEASING HORMONE AGONISTS SUPPRESSES AUTOANTIBODIES IN ENDOMETRIOSIS
    ELROEIY, A
    DMOWSKI, WP
    GLEICHER, N
    RADWANSKA, E
    HARLOW, L
    BINOR, Z
    TUMMON, I
    RAWLINS, RG
    FERTILITY AND STERILITY, 1988, 50 (06) : 864 - 871
  • [49] Gonadotropin-releasing hormone
    Chow, Billy K. C.
    FEBS JOURNAL, 2008, 275 (22) : 5457 - 5457